Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Combination Study of NMS-01940153E and Atezolizumab With or Without Low-Dose Decitabine Priming in Unresectable Hepatocellular Carcinoma After Prior Immune Checkpoint Inhibitors
2024-516737-12-00Phase 2Completed
- Sponsor
- Nerviano Medical Sciences
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2 trial of s 81694 in hepatocellular carcinoma (HCC) (3 arms), sponsored by Nerviano Medical Sciences. Primary endpoint: Objective response rate (ORR). Started Dec 2024; status: completed.
02
Drugs
s 81694
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2024-516737-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516737-12-00.